🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

36+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 16 of 36 recruiting trials for “systemic-vasculitis-associated-with-glomerulopathy”

Phase 1, PHASE2RecruitingNCT06350110 ↗

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

🏥 Essen Biotech📍 1 site📅 Started Jul 2024View details ↗
Phase 1RecruitingNCT06308978 ↗

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

🏥 Fate Therapeutics📍 17 sites📅 Started Mar 2024View details ↗
Phase 4RecruitingNCT06072482 ↗

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

👨‍⚕️ MD, Amgen📍 68 sites📅 Started Feb 2024View details ↗
NARecruitingNCT06277427 ↗

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

👨‍⚕️ Lingli Dong, MD, Tongji Hospital📍 1 site📅 Started Feb 2024View details ↗
RecruitingNCT06794827 ↗

Early-access Avacopan in Real-world ANCA-associated Vasculitis

👨‍⚕️ Y.K. Onno Teng, Leiden University Medical Center📍 1 site📅 Started Nov 2023View details ↗
Phase 1RecruitingNCT06316076 ↗

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

🏥 RenJi Hospital📍 1 site📅 Started Oct 2023View details ↗
Phase 3RecruitingNCT05946564 ↗

A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial

👨‍⚕️ Alexandre Karras, Assistance Publique - Hôpitaux de Paris📍 24 sites📅 Started Oct 2023View details ↗
RecruitingNCT05897684 ↗

Avacostar - (PASS)

🏥 Vifor Fresenius Medical Care Renal Pharma📍 35 sites📅 Started Sep 2023View details ↗
Phase 1RecruitingNCT06056921 ↗

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

👨‍⚕️ Liyun Zhang, M.D, Shanxi Bethune Hospital📍 1 site📅 Started Aug 2023View details ↗
Phase 4RecruitingNCT05962840 ↗

Efficacy and Safety for Rituximab Combined With Telitacicept in the Treatment of ANCA-associated Vasculitis (TTCAAVREM)

👨‍⚕️ Jing Li, MD, Peking Unione Mdecial College Hospital📍 1 site📅 Started Jun 2023View details ↗
Phase 4RecruitingNCT05965284 ↗

Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)

👨‍⚕️ JIng Li, M.D., Peking Unione Mdecial College Hospital📍 1 site📅 Started Mar 2023View details ↗
NARecruitingNCT05364892 ↗

Biocollection of Patients With ANCA Associated Vasculitis

👨‍⚕️ Divi CORNEC📍 1 site📅 Started Oct 2022View details ↗
RecruitingNCT05315141 ↗

Multicenter Cohort Study of AAV in Hunan of China

👨‍⚕️ Xiangcheng Xiao, doctor, Xiangya Hospital of Central South University📍 1 site📅 Started Mar 2022View details ↗
NARecruitingNCT03290456 ↗

Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.

👨‍⚕️ Jean-Christophe LEGA, Pr, Hospices Civils de Lyon📍 45 sites📅 Started Aug 2019View details ↗
RecruitingNCT03004326 ↗

Clinical Transcriptomics in Systemic Vasculitis (CUTIS)

👨‍⚕️ Robert Micheletti, MD, University of Pennsylvania📍 10 sites📅 Started Jan 2017View details ↗
RecruitingNCT02257866 ↗

Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

👨‍⚕️ Peter C Grayson, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)📍 1 site📅 Started Sep 2014View details ↗
← PreviousPage 2 of 2

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →